纽约，纽约 / ACCESS Newswire /2025 年 3 月 18 日/ 如果您在 GSK plc 投资中遭受损失并希望了解根据联邦证券法的潜在赔偿，请点击以下链接获取更多信息：
https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=136884&amp;wire=1
或通过电子邮件联系 Joseph E. Levi 律师，邮箱地址为 jlevi@levikorsinsky.com，或拨打 (212) 363-7500 与我们经验丰富的股东倡导团队联系。
<img height="0" src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/api/iframe.ashx/query-cmVsZWFzZWlkPTEwMDE3NzgmdXJsPWh0dHBzOi8vd3d3LnlvdXR1YmUuY29tL2VtYmVkL1R5bExjc1NFczJN?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="0" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/api/iframe.ashx/query-cmVsZWFzZWlkPTEwMDE3NzgmdXJsPWh0dHBzOi8vd3d3LnlvdXR1YmUuY29tL2VtYmVkL1R5bExjc1NFczJN"/>诉讼： 针对 GSK plc 提起了一项集体诉讼，旨在追回在 2020 年 2 月 5 日至 2022 年 8 月 14 日期间因涉嫌证券欺诈而受到不利影响的股东损失。案件详情： 根据提交的投诉，被告向投资者表示，GSK 基于当时可用的信息和与监管机构的通信，已将 Zantac 从市场上撤回。GSK 还表示，它正在 “继续调查 NDMA 的潜在来源”。被告还向投资者保证，“GSK、FDA 和 EMA（欧洲药品管理局）都独立得出结论，认为没有证据表明雷尼替丁治疗与患者癌症发展的因果关系”，这些发现与 2019 年前发布的其他雷尼替丁数据一致。最后，被告声称他们无法 “量化或可靠估计责任”。这些陈述在实质上是虚假或具有误导性的。实际上，GSK 完全清楚 NDMA 的来源，并在撤回 Zantac 之前已经知道近 40 年。

葛兰素史克

针对葛兰素史克（GSK plc）提起了一项集体诉讼，指控其在 2020 年 2 月 5 日至 2022 年 8 月 14 日期间对股东进行证券欺诈。遭受损失的投资者被鼓励在 2025 年 4 月 7 日之前联系 Levi & Korsinsky LLP，以讨论他们在联邦证券法下的权利和潜在的赔偿。诉讼声称 GSK 在关于 Zantac 撤出市场及相关风险方面误导了投资者。Levi & Korsinsky 在证券诉讼方面有着良好的业绩记录，并为受影响的投资者提供免费的咨询服务

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / If you suffered a loss on your GSK plc investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
<div class="lb-trans">纽约，纽约 / ACCESS Newswire /2025 年 3 月 18 日/ 如果您在 GSK plc 投资中遭受损失并希望了解根据联邦证券法的潜在赔偿，请点击以下链接获取更多信息：
</div>https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=136884&amp;wire=1
<div class="lb-trans">https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=136884&amp;wire=1
</div>or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.
<div class="lb-trans">或通过电子邮件联系 Joseph E. Levi 律师，邮箱地址为 jlevi@levikorsinsky.com，或拨打 (212) 363-7500 与我们经验丰富的股东倡导团队联系。
</div><img height="0" src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/api/iframe.ashx/query-cmVsZWFzZWlkPTEwMDE3NzgmdXJsPWh0dHBzOi8vd3d3LnlvdXR1YmUuY29tL2VtYmVkL1R5bExjc1NFczJN" width="0" original-src="https://app.accessnewswire.com/api/iframe.ashx?releaseid=1001778&amp;url=https%3a%2f%2fwww.youtube.com%2fembed%2fTylLcsSEs2M"/>THE LAWSUIT: A class action securities lawsuit was filed against GSK plc that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 5, 2020 and August 14, 2022.CASE DETAILS: According to the filed complaint, defendants represented to investors that GSK removed Zantac from the market &#34;[b] ased on information available at the time and correspondence with regulators.&#34; GSK also stated that it was &#34;continuing with investigations into the potential source of NDMA.&#34; Defendants also assured investors that &#34;GSK, the FDA, and the EMA [European Medicines Agency] have all independently concluded that there is no evidence of a causal association between ranitidine therapy and the development of cancer in patients,&#34; findings that were &#34;consistent with other ranitidine data published prior to 2019.&#34; Finally, defendants claimed that they could not &#34;quantify or reliably estimate the liability.&#34; These representations were materially false or misleading. In truth, GSK was fully aware of the source of NDMA and had been for nearly 40 years before withdrawing Zantac from the market.WHAT'S NEXT? If you suffered a loss in GSK stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=136884&amp;wire=1 to learn about your rights to seek a recovery. There is no cost or obligation to participate.WHY LEVI &amp; KORSINSKY: Over the past 20 years, Levi &amp; Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.CONTACT: Levi &amp; Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 jlevi@levikorsinsky.com Tel: (212) 363-7500 Fax: (212) 363-7171 https://zlk.com/SOURCE: Levi &amp; Korsinsky, LLP View the original press release on ACCESS Newswire <img height="0" src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTAwMTc3OA" width="0" original-src="https://app.accessnewswire.com/img.ashx?id=1001778"/>
<div class="lb-trans"><img height="0" src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/api/iframe.ashx/query-cmVsZWFzZWlkPTEwMDE3NzgmdXJsPWh0dHBzOi8vd3d3LnlvdXR1YmUuY29tL2VtYmVkL1R5bExjc1NFczJN" width="0" original-src="https://app.accessnewswire.com/api/iframe.ashx?releaseid=1001778&amp;url=https%3a%2f%2fwww.youtube.com%2fembed%2fTylLcsSEs2M"/></div>诉讼： 针对 GSK plc 提起了一项集体诉讼，旨在追回在 2020 年 2 月 5 日至 2022 年 8 月 14 日期间因涉嫌证券欺诈而受到不利影响的股东损失。案件详情： 根据提交的投诉，被告向投资者表示，GSK 基于当时可用的信息和与监管机构的通信，已将 Zantac 从市场上撤回。GSK 还表示，它正在 “继续调查 NDMA 的潜在来源”。被告还向投资者保证，“GSK、FDA 和 EMA（欧洲药品管理局）都独立得出结论，认为没有证据表明雷尼替丁治疗与患者癌症发展的因果关系”，这些发现与 2019 年前发布的其他雷尼替丁数据一致。最后，被告声称他们无法 “量化或可靠估计责任”。这些陈述在实质上是虚假或具有误导性的。实际上，GSK 完全清楚 NDMA 的来源，并在撤回 Zantac 之前已经知道近 40 年。

GSK plc 的投资者应在2025年4月7日之前联系 Levi & Korsinsky 讨论您的权利 - 葛兰素史克